PROMETHEUS® IBS Diagnostic is the First Blood-Based Biomarker Test for IBS
Prometheus
Prometheus continues to deliver innovation in its therapeutics and diagnostics for physicians and their patients who suffer from gastrointestinal diseases.
PROMETHEUS IBS Diagnostic
- The first blood-based biomarker test for IBS
- Provides clear, simple test results to complement the clinical evaluation
- Can help clarify or validate other diagnostic findings
- Delivers tangible evidence to help reassure patients
Irritable Bowel Syndrome (IBS)
IBS is frequently encountered and can be difficult to diagnose
- Affects up to 20% of the US population
- The most common GI diagnosis among gastroenterology practices
- Affects 3.2 times more women than men
- No visible abnormality seen upon endoscopy
- Patients with IBS often go undiagnosed for several years
- Symptoms can resemble other conditions
IBS has been a diagnosis of exclusion
- Many tests are often performed to exclude other diseases
- Rome criteria effectiveness is influenced by subjective information received from patients
- A lack of objective evidence can make an IBS diagnosis difficult for patients to accept
For more information, please go to www.prometheuslabs.com
The PROMETHEUS IBS Diagnostic is not currently available to residents of New York State. |